Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 20
2003 15
2004 21
2005 27
2006 27
2007 24
2008 38
2009 24
2010 22
2011 26
2012 19
2013 21
2014 18
2015 20
2016 15
2017 17
2018 21
2019 35
2020 40
2021 33
2022 29
2023 19
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Results by year

Filters applied: . Clear all
Page 1
Delivery platforms for broadly neutralizing antibodies.
Joshi LR, Gálvez NMS, Ghosh S, Weiner DB, Balazs AB. Joshi LR, et al. Among authors: weiner db. Curr Opin HIV AIDS. 2023 Jul 1;18(4):191-208. doi: 10.1097/COH.0000000000000803. Epub 2023 May 15. Curr Opin HIV AIDS. 2023. PMID: 37265268 Review.
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
Yarchoan M, Gane EJ, Marron TU, Perales-Linares R, Yan J, Cooch N, Shu DH, Fertig EJ, Kagohara LT, Bartha G, Northcott J, Lyle J, Rochestie S, Peters J, Connor JT, Jaffee EM, Csiki I, Weiner DB, Perales-Puchalt A, Sardesai NY. Yarchoan M, et al. Among authors: weiner db. Nat Med. 2024 Apr;30(4):1044-1053. doi: 10.1038/s41591-024-02894-y. Epub 2024 Apr 7. Nat Med. 2024. PMID: 38584166 Free PMC article. Clinical Trial.
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML. Trimble CL, et al. Among authors: weiner db. Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17. Lancet. 2015. PMID: 26386540 Free PMC article. Clinical Trial.
DNA vaccines: prime time is now.
Gary EN, Weiner DB. Gary EN, et al. Among authors: weiner db. Curr Opin Immunol. 2020 Aug;65:21-27. doi: 10.1016/j.coi.2020.01.006. Epub 2020 Apr 4. Curr Opin Immunol. 2020. PMID: 32259744 Free PMC article. Review.
AIDS vaccines.
Emini EA, Weiner DB. Emini EA, et al. Among authors: weiner db. Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S1-2. doi: 10.1586/14760584.3.4.s1. Expert Rev Vaccines. 2004. PMID: 15285701 No abstract available.
DNA vaccines 2014 meeting: Highlights and overview.
Ugen KE, Weiner DB. Ugen KE, et al. Among authors: weiner db. Hum Vaccin Immunother. 2015;11(8):1887-8. doi: 10.1080/21645515.2015.1066947. Hum Vaccin Immunother. 2015. PMID: 26158530 Free PMC article. No abstract available.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L, Gregorio E, Chen Y, Thakur R, Abdel-Mohsen M, Beqiri M, Kiernan M, Perego M, Wang F, Xiao M, Brafford P, Yang X, Xu X, Secreto A, Danet-Desnoyers G, Traum D, Kaestner KH, Huang AC, Hristova D, Wang J, Fukunaga-Kalabis M, Krepler C, Ping-Chen F, Zhou X, Gutierrez A, Rebecca VW, Vonteddu P, Dotiwala F, Bala S, Majumdar S, Dweep H, Wickramasinghe J, Kossenkov AV, Reyes-Arbujas J, Santiago K, Nguyen T, Griss J, Keeney F, Hayden J, Gavin BJ, Weiner D, Montaner LJ, Liu Q, Peiffer L, Becker J, Burton EM, Davies MA, Tetzlaff MT, Muthumani K, Wargo JA, Gabrilovich D, Herlyn M. Somasundaram R, et al. Among authors: weiner d. Nat Commun. 2021 Jan 12;12(1):346. doi: 10.1038/s41467-020-20600-7. Nat Commun. 2021. PMID: 33436641 Free PMC article.
Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers.
Bordoloi D, Kulkarni AJ, Adeniji OS, Pampena MB, Bhojnagarwala PS, Zhao S, Ionescu C, Perales-Puchalt A, Parzych EM, Zhu X, Ali AR, Cassel J, Zhang R, Betts MR, Abdel-Mohsen M, Weiner DB. Bordoloi D, et al. Among authors: weiner db. Sci Adv. 2023 Nov 3;9(44):eadh4379. doi: 10.1126/sciadv.adh4379. Epub 2023 Nov 1. Sci Adv. 2023. PMID: 37910620 Free PMC article.
478 results